Abstract
ARTICLE INFO Article History In the present study, we investigated the potential protective effects of royal jelly against doxorubicin-induced nephrotoxicity in Ehrlich ascites tumor bearing mice. Adult male albino mice were randomly divided into eight groups: the control, royal jelly, doxorubicin, and royal jelly plus doxorubicin groups. Biochemical, oxidative stress, and histopathological and immunohistochemical methods were utilized for evaluation of the reno-toxicity. Blood was collected and analyzed for blood urea nitrogen (BUN), uric acid and creatinine. The renal samples were stored for the measurement of malondialdehyde (MDA), glutathione peroxidase (GSH) and superoxide dismutase (SOD) activities and processed for histopathological examinations. Administration of doxorubicin to mice bearing Ehrlich tumor induced a marked renal dysfunction, characterized with a significant increase in serum BUN, uric acid and creatinine concentrations, and they had higher renal MDA and decreased in GSH and SOD concentrations. In the groups that were feed on RJ in association with DOX, improvement was observed in some oxidative stress parameters and certain other biochemical, histopathological and immunohistochemical parameters. The royal jelly exerted significant protection against renal damage induced by doxorubicin through reduction of the elevated activities of serum renal functions. Moreover, royal jelly blocked doxorubicin-induced lipid peroxidation through decreasing the malondialdehyde formation. In conclusion, royal jelly has a capability to attenuate doxorubicin-induced nephrotoxicity.
Highlights
Cancer is a major health problem worldwide and is the leading cause of human mortality exceeded only by cardiovascular disease (Varmus, 2006)
In experiments on a DOX, the antitumor activities of royal jelly therapy were evaluated on the basis of mean tumor weight after necropsy (Fig. 1)
We evaluated the toxicological effect of the DOX by measuring mean the biochemical analysis of creatinine, blood urea nitrogen (BUN) and uric acid (Table 1)
Summary
Cancer is a major health problem worldwide and is the leading cause of human mortality exceeded only by cardiovascular disease (Varmus, 2006). Most of the currently available anti-cancer drugs fail to differentiate between normal and neoplastic cells or to overcome primary or secondary resistance mechanisms involved in cancer cells. El-kott et al. there is an urgent need of anti-cancer drugs with high potency, less toxicity to non-cancerous cells and unique target of actions (Chari, 1998). Doxorubicin (DXR) is an anthracycline glycoside with broad spectrum of therapeutic activity against a variety of human neoplasms (Giri et al., 2004). The clinical use of DXR has been limited by its undesirable side effects, especially cardiac and renal toxicity (Mohan et al, 2010). Oxidative stress has been associated with DOX-
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
